


THIRD EDITION



# HUMAN BLOOD GROUPS

Geoff Daniels



 WILEY-BLACKWELL


# Human Blood Groups

**Geoff Daniels**

BSc, PhD, FRCPath  
Head of Diagnostics  
International Blood Group Reference Laboratory;  
Senior Research Fellow  
Bristol Institute for Transfusion Sciences,  
NHS Blood and Transplant, Bristol, UK

**Foreword by Ruth Sanger**

**3rd edition**



**WILEY-BLACKWELL**

A John Wiley & Sons, Ltd., Publication

This edition first published 2013 © 1995, 2002, 2013 by Geoff Daniels

Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell's publishing program has been merged with Wiley's global Scientific, Technical and Medical business to form Wiley-Blackwell.

*Registered office:* John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

*Editorial offices:* 9600 Garsington Road, Oxford, OX4 2DQ, UK  
The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK  
111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com/wiley-blackwell](http://www.wiley.com/wiley-blackwell)

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

*Library of Congress Cataloging-in-Publication Data*  
Daniels, Geoff.

Human blood groups : Geoff Daniels ; foreword to first edition by Ruth Sanger. – 3rd ed.  
p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-4443-3324-4 (hardback : alk. paper) – ISBN 978-1-118-49354-0 (epub) – ISBN 978-1-118-49359-5 (obook) – ISBN 978-1-118-49361-8 (emobi) – ISBN 978-1-118-49362-5 (epdf)

I. Title.

[DNLM: 1. Blood Group Antigens. WH 420]  
612.1'1825–dc23

2012040684

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover image (top right): Homology model of an Rh protein (RhD or RhCE) courtesy of Dr Nicholas Burton, University of Bristol, UK. Blood bag image: © iStockPhoto / pictorico

Cover design by Garth Stewart

Set in 9.25/11.5 pt Minion by Toppan Best-set Premedia Limited  
Printed and bound in Singapore by Markono Print Media Pte Ltd

# Foreword to 1st edition

It is a particular pleasure for me to welcome this new book on human blood groups, the more so since it emanates from the Medical Research Council's Blood Group Unit. For 25 years this Unit devoted its energies to the search for new red cell antigens and the application of those already known to various problems, particularly to human genetics. During these years Rob Race and I produced six editions of *Blood Groups in Man*.

Dr Geoff Daniels joined the Unit in 1973 on Dr Race's retirement; soon after, concurrently with the Unit's move from the Lister Institute to University College, the scope of the Unit's interest was broadened.

Having been divorced from blood groups and otherwise occupied in 12 years of retirement, I am delighted and astonished at the rapid advances made in recent

years. The number of blood group loci have increased to 23 and all except one have found their chromosomal home. The biochemical backgrounds of most of the corresponding antigens are defined and hence several high and low incidence antigens gathered into systems. The molecular basis of many red cell antigens has provided an explanation for some confusing serological relationships which were observed many years before.

Dr Daniels is to be congratulated on his stamina in producing a comprehensive text and reference book on human blood groups, for which many scientists will be grateful.

Ruth Sanger  
December 1994



# Preface to the third edition

The primary purpose of this book, like the first two editions, is to describe human blood group antigens and their inheritance, the antibodies that define them, the structure and functions of the red cell membrane macromolecules that carry them, and the genes that encode them or control their biosynthesis. In addition, this book provides information on the clinical relevance of blood groups and on the importance of blood group antibodies in transfusion medicine in particular.

The second edition of *Human Blood Groups* was published in 2002; this new edition will appear 11 years later. There have been many new findings in the blood group world over those years. In order to prevent the book from becoming too cumbersome, my goal has been to produce a third edition roughly the same size as the first two. I have tried to do this without eliminating anything too important, although this has not been easy, with so much new material to include. Since 2002, about 69 new blood group antigens and seven new blood group systems have been identified, and all of the 38 genes representing those systems have been cloned and sequenced.

In the preface of the sixth edition of *Blood Groups in Man*, the predecessor of *Human Blood Groups*, Race and Sanger wrote, 'Here is the last edition of this book: the subject has grown to need more than our two pencils'.

Well, here is the last edition of *Human Blood Groups*; the subject is rapidly growing too vast to be contained in a textbook. In the previous two editions I strove to include all fully validated blood group antigens and genetic changes associated with their expression or loss of expression. This has proved impossible and pointless in this edition so, although the genetic bases of all the important blood group polymorphisms are described, in many cases the reader is directed to web sites for a more complete list of mutations, particularly those responsible for null phenotypes. In the next few years, next-generation sequencing will become readily available and affordable, and the number of genetic variations associated with red cell change will increase exponentially.

I wish to thank again all the people who helped me produce the first two editions, in particular Patricia Tippet, Carole Green, David Anstee, and Joan Daniels. I would like to add my thanks to Dr Nicholas Burton at the University of Bristol who provided many of the protein models for this edition. Finally I would like to thank all the numerous colleagues from around the world who have provided so much of the information in this book, in published or unpublished form, over so many years.

Geoff Daniels

# Some abbreviations used

ADP	Adenosine diphosphate	GTB	B-transferase
ATP	Adenosine triphosphate	HCF	Hydatid cyst fluid
AET	2-aminoethylisothiourea bromide	HDFN	Haemolytic disease of the fetus and newborn
AIHA	Autoimmune haemolytic anaemia	HTR	Haemolytic transfusion reaction
bp	Base-pair	IAT	Indirect antiglobulin test
CDA	Congenital dyserythropoietic anaemia	ISBT	International Society of Blood Transfusion (may refer to ISBT terminology)
cDNA	Complimentary DNA	kb	Kilo-bases
CFU-E	Colony-forming unit-erythroid	kDa	Kilo-Daltons
Da	Daltons	MAIEA	Monoclonal antibody immobilisation of erythrocyte antigens
DAT	Direct antiglobulin test	mRNA	Messenger ribonucleic acid
DNA	Deoxyribonucleic acid	MW	Molecular weight
DTT	Dithiothreitol	PCR	Polymerase chain reaction
Gal	Galactose	RFLP	Restriction fragment-length polymorphism
GalNAc	N-acetylgalactosamine	RNA	Ribonucleic acid
GlcNAc	N-acetylglucosamine	SDS PAGE	Sodium dodecyl sulphate polyacrylamide gel electrophoresis
GDP	Guanosine diphosphate	SNP	Single nucleotide polymorphism
GPI	Glycosylphosphatidylinositol		
GSL	Glycosphingolipid		
GTA	A-transferase		

# Contents to 1st edition

Foreword, vii

Preface to the third edition, viii

Some abbreviations used, ix

1 Human blood groups: introduction, 1

2 ABO, H, and Lewis systems, 11

3 MNS blood group system, 96

4 P1PK, Globoside, and FORS blood group systems, plus some other related blood groups, 162

5 Rh and RHAG blood group systems, 182

6 Lutheran blood group system, 259

7 Kell and Kx blood group systems, 278

8 Duffy blood group system, 306

9 Kidd blood group system, 325

10 Diego blood group system, 336

11 Yt blood group system, 354

12 Xg blood group system, 359

13 Scianna blood group system, 371

14 Dombrock blood group system, 376

15 Colton blood group system, 384

16 LW blood group system, 391

17 Chido/Rodgers blood group system, 400

18 Gerbich blood group system, 410

19 Cromer blood group system, 427

20 Knops blood group system and the Cost antigens, 439

- 21 Indian blood group system and the AnWj antigen, 449
- 22 Ok blood group system, 457
- 23 Raph blood group system, 461
- 24 JMH blood group system, 465
- 25 I and i antigens, and cold agglutination, 469
- 26 Gill blood group system, 485
- 27 Junior and Langereis blood group systems, 487
- 28 Er antigens, 493
- 29 Low frequency antigens, 495
- 30 High frequency antigens, including Vel, 500
- 31 Sid antigen, 505
- 32 HLA (Human Leucocyte-Associated) Class I antigens on red cells, 512
- 33 Polyagglutination and cryptantigens, 515
- Index, 524



# Human Blood Groups: Introduction

1.1 Introduction, 1

1.2 Blood group terminology, 3

1.3 Chromosomal location of blood group genes, 5

1.4 DNA analysis for blood group testing, 5

1.5 Structures and functions of blood group antigens, 7

## 1.1 Introduction

What is the definition of a blood group? Taken literally, any variation or polymorphism detected in the blood could be considered a blood group. However, the term blood group is usually restricted to blood cell surface antigens and generally to red cell surface antigens. This book focuses on the inherited variations in human red cell membrane proteins, glycoproteins, and glycolipids. These variations are detected by alloantibodies, which occur either 'naturally', due to immunisation by ubiquitous antigens present in the environment, or as a result of alloimmunisation by human red cells, usually introduced by blood transfusion or pregnancy. Although it is possible to detect polymorphism in red cell surface proteins by other methods such as DNA sequence analysis, such variants cannot be called blood groups unless they are defined by an antibody.

Blood groups were discovered at the beginning of the twentieth century when Landsteiner [1,2] noticed that plasma from some individuals agglutinated the red cells from others. For the next 45 years, only those antibodies that directly agglutinate red cells could be studied. With the development of the antiglobulin test by Coombs, Mourant, and Race [3,4] in 1945, non-agglutinating antibodies could be detected and the science of blood group serology blossomed. There are now 339 authenticated blood group antigens, 297 of which fall into one of 33 blood group systems, genetically discrete groups of

antigens controlled by a single gene or cluster of two or three closely linked homologous genes (Table 1.1).

Most blood group antigens are synthesised by the red cell, but the antigens of the Lewis and Chido/Rodgers systems are adsorbed onto the red cell membrane from the plasma. Some blood group antigens are detected only on red cells; others are found throughout the body and are often called histo-blood group antigens.

Biochemical analysis of blood group antigens has shown that they fall into two main types:

1 protein determinants, which represent the primary products of blood group systems; and

2 carbohydrate determinants on glycoproteins and glycolipids, in which the products of the genes controlling antigen expression are glycosyltransferase enzymes.

Some antigens are defined by the amino acid sequence of a glycoprotein, but are dependent on the presence of carbohydrate for their recognition serologically. In this book the three-letter code for amino acids is mainly used, though the single-letter code is often employed in long sequences and in some figures. The code is provided in Table 1.2.

In recent years, molecular genetical techniques have been introduced into the study of human blood groups and now most of the genes governing blood group systems have been cloned and sequenced (Table 1.1). Many serological complexities of blood groups are now explained at the gene level by a variety of mechanisms, including point mutation, unequal crossing-over, gene conversion, and alternative RNA splicing.



Table 1.1 Blood group systems.

No.	Name	Symbol*	No. of antigens	Associated membrane structures	CD no.	HGNC symbol(s)	Chromosome
001	ABO	ABO	4	Carbohydrate		ABO	9
002	MNS	MNS	46	Glycophorins, GPA, GPB	CD235 A & B	GYP A, GYP B, GYPE	4
003	PIPK	PIPK	3	Carbohydrate		A4GALT	22
004	Rh	RH	54	Rh family, RhD, RhCE	CD240 D & CE	RHD, RHCE	1
005	Lutheran	LU	20	IgSF	CD239	BCAM	19
006	Kell	KEL	35	Endopeptidase	CD238	KEL	7
007	Lewis	LE	6	Carbohydrate		FUT3	19
008	Duffy	FY	5	G protein-coupled SF, chemokine receptor	CD234	DARC	1
009	Kidd	JK	3	Urea transporter		SLC14A1	18
010	Diego	DI	22	Band 3, anion exchanger (AE1)	CD233	SLC4A1	17
011	Yt	YT	2	Acetylcholinesterase		ACHE	7
012	Xg	XG	2	Glycoproteins	CD99**	XG, CD99	X/Y
013	Scianna	SC	7	IgSF, erythroblast membrane-associated protein		ERMAP	1
014	Dombrock	DO	8	ADP-ribosyltransferase 4	CD297	ART4	12
015	Colton	CO	4	Aquaporin SF, aquaporin-1		AQP1	7
016	Landsteiner-Wiener	LW	3	IgSF, intercellular adhesion molecule-4	CD242	ICAM4	19
017	Chido/Rodgers	CH/RG	9	Complement components C4A, C4B		C4A, C4B	6
018	H	H	1	Carbohydrate, Type 2 H	CD173	FUT1	19
019	Kx	XK	1	Xk protein		XK	X
020	Gerbich	GE	11	Glycophorins, GPC, GPD	CD236	GYP C	2
021	Cromer	CROM	18	CCP SF, decay-accelerating factor	CD55	CD55	1
022	Knops	KN	9	CCP SF, complement regulator-1	CD35	CR1	1
023	Indian	IN	4	Link module SF of proteoglycans	CD44	CD44	11
024	Ok	OK	3	IgSF, basigin	CD147	BSG	19
025	Raph	RAPH	1	Tetraspanin SF	CD151	CD151	11
026	John Milton Hagen	JMH	6	Semaphorin SF	CD108	SEMA7A	15
027	I	I	1	Carbohydrate		GCNT2	6
028	Globoside	GLOB	1	Carbohydrate, globoside		B3GALT3	3
029	Gill	GIL	1	Aquaporin SF, aquaporin-3		AQP3	9
030	RHAG	RHAG	4	Rh family, Rh-associated glycoprotein	CD241	RHAG	6
031	Forssman	FORS	1	Carbohydrate, Forssman glycolipid		GBCT1	9
032	Junior	JR	1	ATP-binding cassette transporter ABCG2		ABCG2	4
033	Lan	LAN	1	ATP-binding cassette transporter ABCB6		ABCB6	2

HGNC, Human Genome Organisation Gene Nomenclature Committee; SF, superfamily; IgSF, immunoglobulin superfamily; CCP, complement control protein.

\*ISBT gene name when in italics.

\*\*Does not include Xg glycoprotein.

**Table 1.2** The 20 common amino acids: one- and three-letter codes.

A	Ala	Alanine
C	Cys	Cysteine
D	Asp	Aspartic acid
E	Glu	Glutamic acid
F	Phe	Phenylalanine
G	Gly	Glycine
H	His	Histidine
I	Ile	Isoleucine
K	Lys	Lysine
L	Leu	Leucine
M	Met	Methionine
N	Asn	Asparagine
P	Pro	Proline
Q	Gln	Glutamine
R	Arg	Arginine
S	Ser	Serine
T	Thr	Threonine
V	Val	Valine
W	Trp	Tryptophan
Y	Tyr	Tyrosine

Discovery of the ABO blood groups first made blood transfusion feasible and disclosure of the Rh antigens led to the understanding, and subsequent prevention, of haemolytic disease of the fetus and newborn (HDFN). Although ABO and Rh are the most important systems in transfusion medicine, many other blood group antibodies are capable of causing a haemolytic transfusion reaction (HTR) or HDFN. Red cell groups have been important tools in forensic science, although this role was diminished with the introduction of HLA testing and has recently been displaced by DNA 'fingerprinting'. For many years blood groups were the best human genetic markers and played a major part in the mapping of the human genome.

Blood groups still have much to teach us. Because red cells are readily available and haemagglutination tests relatively easy to perform, the structure and genetics of the red cell membrane proteins and lipids are understood in great detail. With the unravelling of the complexities of blood group systems by molecular genetic techniques, much has been learnt about the mechanisms responsible for the diversification of protein structures and the nature of the human immune response to proteins of different shapes resulting from variations in amino acid sequence.

## 1.2 Blood group terminology

The problem of providing a logical and universally agreed nomenclature has dogged blood group serologists almost since the discovery of the ABO system. Before going any further, it is important to understand how blood groups are named and how they are categorised into systems, collections, and series.

### 1.2.1 An internationally agreed nomenclature

The International Society of Blood Transfusion (ISBT) Working Party on Red Cell Immunogenetics and Blood Group Terminology was set up in 1980 to establish a uniform nomenclature that is 'both eye and machine readable'. Part of the brief of the Working Party was to produce a nomenclature 'in keeping with the genetic basis of blood groups' and so a terminology based primarily around the blood group systems was devised. First the systems and the antigens they contained were numbered, then the high and low frequency antigens received numbers, and then, in 1988, collections were introduced. Numbers are never recycled: when a number is no longer appropriate it becomes obsolete.

Blood group antigens are categorised into 33 systems, seven collections, and two series. The Working Party produced a monograph in 2004 to describe the terminology [5], which was most recently updated in 2011 [6]. Details can also be found on the ISBT web site [7].

### 1.2.2 Antigen, phenotype, gene and genotype symbols

Every authenticated blood group antigen is given a six-digit identification number. The first three digits represent the system (001 to 033), collection (205 to 213), or series (700 for low frequency, 901 for high frequency); the second three digits identify the antigen. For example, the Lutheran system is system 005 and Lu<sup>a</sup>, the first antigen in that system, has the number 005001. Each system also has an alphabetical symbol: that for Lutheran is LU. So Lu<sup>a</sup> is also LU001 or, because redundant sinistral zeros may be discarded, LU1. For phenotypes, the system symbol is followed by a colon and then by a list of antigens present, each separated by a comma. If an antigen is known to be absent, its number is preceded by a minus sign. For example, Lu(a-b+) becomes LU:-1,2.

Devising a modern terminology for blood group alleles is more complex. One antigen, the absence of an antigen, or the weakness or absence of all antigens of a system

may be encoded by several or many alleles. Over the last few years the Working Party has been developing a new terminology for blood group alleles. Unfortunately at the time of publication of this book, it was still incomplete, controversial, and in draft form. Consequently, it has only partially been used in this book. Basically, alleles have the system symbol followed by an asterisk followed in turn by a number or series of numbers, separated by full stops, representing the encoded antigen and the allele number. Alternatively, in some cases a letter can be used instead of a number. For example, *Lu<sup>a</sup>* allele can be *LU\*01* or *LU\*A*. Genotypes have the symbol followed by an asterisk followed by the two alleles separated by a stroke. For example, *Lu<sup>a</sup>/Lu<sup>b</sup>* becomes *LU\*01/02* or *LU\*A/B*. The letters N and M represent null and mod. For example, one of the inactive *Lu<sup>b</sup>* alleles responsible for a null phenotype is *LU\*02N.01*, the 02 representing the *Lu<sup>b</sup>* allele, even though no *Lu<sup>b</sup>* antigen is expressed. Genes, alleles, and genotypes are italicised. For lists of blood group alleles in the ISBT and other terminologies see the ISBT and dbRBC web sites [7,8].

Symbols for all human genes are provided by the Human Genome Organisation (HUGO) Gene Nomenclature Committee (HGNC) [9]. These often differ from the ISBT symbols, as the HGNC symbols reflect the function of the gene product (Table 1.1). When referring to alleles defining blood group antigens, the ISBT gene symbol is preferred because the HGNC symbols often change with changes in the perceived functions of the gene product.

### 1.2.3 Blood group systems

A blood group system consists of one or more antigens, governed by a single gene or by a complex of two or more very closely linked homologous genes with virtually no recombination occurring between them. Each system is genetically discrete from every other blood group system. All of the genes representing blood group systems have been identified and sequenced.

In some systems the gene directly encodes the blood group determinant, whereas in others, where the antigen is carbohydrate in nature, the gene encodes a transferase enzyme that catalyses biosynthesis of the antigen. A, B, and H antigens, for example, may all be located on the same macromolecule, yet H-glycosyltransferase is produced by a gene on chromosome 19 while the A- and B-transferases, which require H antigen as an acceptor substrate, are products of a gene on chromosome 9. Hence H belongs to a separate blood group system

**Table 1.3** Blood group collections.

No.	Name	Symbol	No. of antigens	Chapter
205	Cost	COST	2	20
207	Ii	I	1	25
208	Er	ER	3	28
209		GLOB	2	4
210	(Le <sup>c</sup> & Le <sup>d</sup> )		2	2
212	Vel	VEL	2	30
213	MNCHO	MNCHO	6	3

from A and B (Chapter 2). Regulator genes may affect expression of antigens from more than one system: *In(Lu)* down-regulates expression of antigens from both Lutheran and P systems (Chapter 6); mutations in *RHAG* are responsible for Rh<sub>null</sub> phenotype, but may also cause absence of U (MNS5) and Fy5 antigens (Chapter 5). So absence of an antigen from cells of a null-phenotype is never sufficient evidence for allocation to a system. Four systems consist of more than one gene locus: MNS has three loci; Rh, Xg, and Chido/Rodgers have two each.

### 1.2.4 Collections

Collections were introduced into the terminology in 1988 to bring together genetically, biochemically, or serologically related sets of antigens that could not, at that time, achieve system status, usually because the gene identity was not known. Thirteen collections have been created, six of which have subsequently been declared obsolete (Table 1.3): the Gerbich (201), Cromer (202), and Indian (203) collections have now become systems; Auberger (204), Gregory (206), and Wright (211) have been incorporated into the Lutheran, Dombrock, and Diego systems, respectively.

### 1.2.5 Low frequency antigens, the 700 series

Red cell antigens that do not fit into any system or collection and have an incidence of less than 1% in most populations tested are given a 700 number (see Table 29.1). The 700 series currently consists of 18 antigens. Thirty-six 700 numbers are now obsolete as the corresponding antigens have found homes in systems or can no longer be defined owing to lack of reagents.

### 1.2.6 High frequency antigens, the 901 series

Originally antigens with a frequency greater than 99% were placed in a holding file called the 900 series, equivalent to the 700 series for low frequency antigens. With the establishment of the collections, so many of these 900 numbers became obsolete that the whole series was abandoned and the remaining high frequency antigens were relocated in a new series, the 901 series, which now contains six antigens (see Table 30.1). The 901 series antigen Jr<sup>a</sup> and Lan became systems 32 and 33 in 2012 when their genes were identified (Chapter 27).

### 1.2.7 Blood group terminology used in this book

The ISBT terminology provides a uniform nomenclature for blood groups that can be continuously updated and is suitable for storage of information on computer databases. The Terminology Working Party does not expect, or even desire, that the numerical terminology be used in all circumstances, although it is important that it should be understood so that the genetically based classification is understood. In this book, the alternative, 'popular' nomenclature, recommended by the Working Party [5], will generally be used. This does not reflect a lack of confidence in the numerical terminology, but is simply because most readers will not be well acquainted with blood group numbers and will find the contents of the book easier to digest if familiar names are used. The numerical terminology will be provided throughout the book in tables and often, in parentheses, in the text.

The order of the chapters of this book is based on the order of the blood group systems, collections, and series. There are, however, a few exceptions, the most notable of which are the ABO, H, and Lewis systems, which appear together in one mega-chapter (Chapter 2), because they are so closely related, biochemically.

## 1.3 Chromosomal location of blood group genes

Blood groups have played an important role as human gene markers. In 1951, when the Lutheran locus was shown to be genetically linked to the locus controlling ABH secretion, blood groups were involved in the first recognised human autosomal linkage and, consequently,

the first demonstration of recombination resulting from crossing-over in humans [10,11]. When, in 1968, the Duffy blood group locus was shown to be linked to an inherited visible deformity of chromosome 1, it became the first human gene locus assigned to an autosome [12]. Since all blood group system genes have now been sequenced, all have been assigned to a chromosome (Table 1.1, Figure 1.1).

## 1.4 DNA analysis for blood group testing

Since the discovery of blood groups in 1900, most blood group testing has been carried out by serological means. With the application of gene cloning and sequencing of blood group genes at the end of the twentieth century, however, it became possible to predict blood group phenotypes from the DNA sequence. The molecular bases for almost all of the clinically significant blood group polymorphisms have been determined, so it is possible to carry out blood grouping by DNA analysis with a high degree of accuracy.

There are three main reasons for using molecular methods, rather than serological methods, for red cell blood grouping:

- 1 when we need to know a blood group phenotype, but do not have a suitable red cell sample;
- 2 when molecular testing will provide more or better information than serological testing; and
- 3 when molecular testing is more efficient or more cost effective than serological testing.

### 1.4.1 Clinical applications of molecular blood grouping

A very important application is determination of fetal blood group in order to assess the risk of HDFN. This is a non-invasive procedure carried out on cell-free fetal DNA in the maternal plasma, which represents 3–6% of the cell-free DNA in the plasma of a pregnant woman [13]. This technology is most commonly applied to RhD typing (Section 5.7), but also to Rh C, c, and E, and K of the Kell system.

Molecular methods are routinely used for extended blood group typing (beyond ABO and RhD) on multiply transfused patients, where serological methods are unsatisfactory because of the presence of transfused red cells. These patients are usually transfusion dependent and






Figure 1.1 Human male chromosomes, showing location of blood group and related genes.

knowledge of their blood groups means that matched blood can be provided in an attempt to save them from making multiple antibodies and, if the patient is already immunised, to facilitate antibody identification. Molecular methods can be used for determining blood group phenotypes on red cells that are DAT-positive (i.e. coated with immunoglobulin), which makes serological testing difficult. This is particularly useful in helping to identify

underlying alloantibodies in patients with autoimmune haemolytic anaemia (AIHA).

There are numerous variants of D. Some result in loss of D epitopes and some in reduced expression of D; most probably involve both (Section 5.6). Individuals with some of these variant D antigens can make a form of alloanti-D that detects those epitopes lacking from their own red cells. In many cases D variants cannot be



distinguished by serological methods, so molecular methods are often used for their identification. This assists in the selection of the most appropriate red cells for transfusion in order to avoid immunisation whilst conserving D-negative blood. There are some rare D antigens, such as DEL, that are not detected by routine serological methods. Consequently, blood donors with these phenotypes would be labelled as D-negative, although evidence exists that transfusion of DEL red cells can immunise a D-negative recipient to make anti-D. As DEL and other very weak forms of D are associated with the presence of a mutated *RHD* gene, they can be detected by molecular methods. In some transfusion services all D-negative donors are tested for the presence of *RHD*, although this is still not generally considered necessary (Section 5.6.9).

Molecular tests can be used for screening for donors when serological reagents are of poor quality or in short supply. For example, anti-Do<sup>a</sup> and -Do<sup>b</sup> have the potential to be haemolytic, yet satisfactory reagents are not available for finding donors for a patient with one of these antibodies (Chapter 14). Some Rh variants, such as hr<sup>B</sup>-negative and hr<sup>S</sup>-negative, are relatively common in people of African origin but are difficult to detect serologically (Section 5.9.5). Molecular tests are often employed to assist in finding suitable blood for patients with sickle cell disease, to reduce alloimmunisation and the risks of delayed HTRs [14,15].

Molecular methods are extremely useful in the blood group reference laboratory for helping to solve serological difficult problems.

In most countries, all blood donors are tested for ABO and D, but often a proportion of the donors are also tested for additional blood group antigens, especially C, c, E, e, and K, but sometimes also C<sup>w</sup>, M, S, s, Fy<sup>a</sup>, Fy<sup>b</sup>, Jk<sup>a</sup>, and Jk<sup>b</sup>. This testing is usually performed by automated serological methods, but it is likely that in the future these serological methods will be replaced by molecular methods [16–18]. Molecular typing for this purpose has already been introduced in some services [19,20]. Molecular methods are more accurate than serological methods, they are more suited to high-throughput methods, and they are either cheaper or are likely to become so in the near future. This provides justification for a switch of technologies.

### 1.4.2 Current and future technologies

Laboratories performing blood group testing on cell-free fetal DNA in the maternal plasma generally use real-time quantitative PCR with Taqman technology, but

an alternative technology that is becoming available involves the application of matrix-assisted laser desorption/ionisation time-of-flight (MALDI TOF) mass spectrometry [21].

For other applications of molecular blood grouping, many laboratories use methods traditionally applied to single nucleotide polymorphism (SNP) testing, involving PCR with the application of restriction enzymes or PCR with allele-specific primers, followed by gel electrophoresis. Other technologies that are becoming more commonly used involve the application of allele-specific extension of primers tagged with single fluorescent nucleotides, pyrosequencing, DNA microarray technology, on chips or coloured beads coated with oligonucleotides, and MALDI TOF [18,22]. The future of molecular blood grouping and of molecular diagnostics probably lies with next generation (massively parallel) sequencing, which will be truly high-throughput [23,24]. Next generation sequencing is an extremely powerful technology that provides the capacity to sequence many regions of the genome in numerous different individuals in one run, including fetal DNA from maternal plasma [25].

## 1.5 Structures and functions of blood group antigens

For the half-century following Landsteiner's discovery, human blood groups were understood predominantly as patterns of inherited serological reactions. From the 1950s some structural information was obtained through biochemical analyses, firstly of the carbohydrate antigens and then of the proteins. In 1986, *GYP A*, the gene encoding the MN antigens, was cloned and this led into the molecular genetic era of blood groups. A great deal is now known about the structures of many blood group antigens, yet remarkably little is known about their functions and most of what we do know has been deduced from their structures. Functional aspects of blood group antigens are included in the appropriate chapters of this book; provided here is a synopsis of the relationship between their structures and putative functions. The subject is reviewed in [26] and computer modelling of blood group proteins, which gives detailed information about protein structure, is reviewed in [27].

### 1.5.1 Membrane transporters

Membrane transporters facilitate the transfer of biologically important molecules in and out of the cell. In the

red cell they are polytopic, crossing the membrane several times, with cytoplasmic N- and C-termini, and are *N*-glycosylated on one of the external loops. Band 3, the Diego blood group antigen (Chapter 10) is an anion exchanger, the Kidd glycoprotein (Chapter 9) is a urea transporter, the Colton glycoprotein is a water channel (Chapter 15), the Gill glycoprotein is a water and glycerol channel (Chapter 26), and the Lan and Junior glycoproteins are ATP-fuelled transporters of porphyrin and uric acid (Chapter 27). Band 3 is at the core of a membrane macrocomplex, which contains the Rh proteins and the Rh-associated glycoprotein, which probably function as a CO<sub>2</sub> channel (Chapters 5 and 10).

### 1.5.2 Receptors and adhesion molecules

The Duffy glycoprotein is polytopic, but has an extracellular N-terminus. It is a member of the G protein-coupled superfamily of receptors and functions as a receptor for chemokines (Chapter 8).

The glycoproteins carrying the antigens of the Lutheran (Chapter 6), LW (Chapter 16), Scianna (Chapter 13), and Ok (Chapter 22) systems are members of the immunoglobulin superfamily (IgSF). The IgSF is a large family of receptors and adhesion molecules with extracellular domains containing different numbers of repeating domains with sequence homology to immunoglobulin domains. The functions of these structures on red cells are not known, but there is evidence to suggest that the primary functional activities of the Lutheran and LW glycoproteins occur during erythropoiesis, with LW probably playing a role in stabilising the erythropoietic islands.

The Indian antigen (CD44), a member of the link module superfamily, functions as an adhesion molecule in many tissues, but its erythroid function is unknown (Chapter 21). The glycoproteins of the Xg (Chapter 12) and JMH (Chapter 24) systems also have structures that suggest they could function as receptors and adhesion molecules. The Raph antigen, a tetraspanin, may associate with integrin in red cell progenitors to generate complexes that bind the extracellular matrix (Chapter 23).

### 1.5.3 Complement regulatory glycoproteins

Red cells have at least three glycoproteins that function to protect the cell from destruction by autologous complement. The Cromer glycoprotein, decay-accelerating factor (Chapter 19), and the Knops glycoprotein, complement receptor-1 (CR1) (Chapter 20), belong to the complement control protein superfamily; CD59 is not

polymorphic and does not have blood group activity (Chapter 19). The major function of red cell CR1 is to bind and process C3b/C4b coated immune complexes and to transport them to the liver and spleen for removal from the circulation.

### 1.5.4 Enzymes

Two blood group glycoproteins have enzymatic activity. The Yt glycoprotein is acetylcholinesterase, a vital enzyme in neurotransmission (Chapter 11), and the Kell glycoprotein is an endopeptidase that can cleave a biologically inactive peptide to produce the active vasoconstrictor, endothelin (Chapter 7). The red cell function for both of these enzymes is unknown. The Dombrock glycoprotein belongs to a family of ADP-ribosyltransferases, but there is no evidence that it is an active enzyme (Chapter 14).

### 1.5.5 Structural components

The shape and integrity of the red cell is maintained by the cytoskeleton, a network of glycoproteins beneath the plasma membrane. At least two blood group glycoproteins anchor the membrane to its skeleton: band 3, the Diego antigen (Chapter 10), and glycophorin C and its isoform glycophorin D, the Gerbich blood group antigens (Chapter 18). Mutations in the genes encoding these proteins can result in abnormally shaped red cells. In addition, there is evidence that glycoproteins of the Lutheran (Chapter 6), Kx (Chapter 7), and RHAG (Chapter 5) systems interact with the cytoskeleton and their absence is associated with some degree of abnormal red cell morphology.

### 1.5.6 Components of the glycocalyx

Glycophorin A, the MN antigen (Chapter 3), band 3 are the two most abundant glycoproteins of the red cell surface. The *N*-glycans of band 3, together with those of the glucose transporter, provide the majority of red cell ABH antigens, which are also expressed on other glycoproteins and on glycolipids (Chapter 2). The extracellular domains of glycophorin A and other glycophorin molecules are heavily *O*-glycosylated. Carbohydrate at the red cell surface constitutes the glycocalyx, or cell coat, an extracellular matrix of carbohydrate that protects the cell from mechanical damage and microbial attack.

### 1.5.7 What is the biological significance of blood group polymorphism?

Very little is known about the biological significance of the polymorphisms that make blood groups alloantigenic. In any polymorphism one of the alleles is likely to

have, or at least to have had in the past, a selective advantage in order to achieve a significant frequency in a large population, though genetic drift and founder effects may also have played a part [28]. Glycoproteins and glycolipids carrying blood group activity are often exploited by pathogenic micro-organisms as receptors for attachment to the cells and subsequent invasion; surviving malaria possibly being the most significant force affecting blood group expression. In some cases, however, selection may have nothing to do with red cells; the target for the parasite could be other cells that carry the protein. It is likely that most blood group polymorphism is a relic of the selective balances that can result from mutations making cell surface structures less suitable as pathogen receptors and resultant adaptation of the parasite in response to these selective pressures. It is important to remember that whilst blood group polymorphism undoubtedly arose from the effects of selective pressures, these factors may have disappeared long ago, so that little hope remains of ever identifying them. To quote Darwin (*The Origin of Species*, 1859), 'The chief part of the organisation of any living creature is due to inheritance; and consequently, though each being assuredly is well fitted for its place in nature, many structures have now no very close and direct relations to present habits of life'.

## References

- Landsteiner K. Zur Kenntnis der antifermentativen, lytischen und agglutinierenden Wirkungen des Blutserums und der Lymphe. *Zbl Bakt* 1900;27:357–366.
- Landsteiner K. Über Agglutinationserscheinungen normalen menschlichen Blutes. *Wien Klein Wochenschr* 1901;14:1132–1134.
- Coombs RRA, Mourant AE, Race RR. Detection of weak and 'incomplete' Rh agglutinins: a new test. *Lancet* 1945; ii:15.
- Coombs RRA, Mourant AE, Race RR. A new test for detection of weak and 'incomplete' Rh agglutinins. *Br J Exp Path* 1945;26:255–266.
- Daniels GL and members of the Committee on Terminology for Red Cell Surface Antigens. Blood group terminology 2004. *Vox Sang* 2004;87:304–316.
- Storry JR and members of the ISBT Working Party on red cell immunogenetics and blood group terminology: Berlin report. *Vox Sang* 2011;101:77–82.
- The International Society of Blood Transfusion Red Cell Immunogenetics and Blood Group Terminology Working Party. <http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-terminology> (last accessed 5 October 2012).
- Blood Group Antigen Gene Mutation Database (dbRBC). <http://www.ncbi.nlm.nih.gov/projects/gv/mhc/xslcgi.cgi?cmd=bgmut/home> (last accessed 5 October 2012).
- HUGO Gene Nomenclature Committee. <http://www.genenames.org> (last accessed 5 October 2012).
- Mohr J. A search for linkage between the Lutheran blood group and other hereditary characters. *Acta Path Microbiol Scand* 1951;28:207–210.
- Mohr J. Estimation of linkage between the Lutheran and the Lewis blood groups. *Acta Path Microbiol Scand* 1951;29:339–344.
- Donahue RP, Bias WB, Renwick JH, McKusick VA. Probable assignment of the Duffy blood group locus to chromosome 1 in man. *Proc Natl Acad Sci USA* 1968;61: 949–955.
- Daniels G, Finning K, Martin P, Massey E. Non-invasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. *Prenat Diagn* 2009;29:101–107.
- Pham B-N, Peyrard T, Juszczak G, *et al.* Analysis of RhCE variants among 806 individuals in France: consideration for transfusion safety, with emphasis on patients with sickle cell disease. *Transfusion* 2011;51:1249–1260.
- Wilkinson K, Harris S, Gaur P, *et al.* Molecular typing augments serologic testing and allows for enhanced matching of red blood cell for transfusion in patients with sickle cell disease. *Transfusion* 2012;52:381–388.
- Avent ND. Large-scale blood group genotyping: clinical implications. *Br J Haematol* 2008;144:3–13.
- Anstee DJ. Red cell genotyping and the future of pretransfusion testing. *Blood* 2009;114:248–256.
- Veldhuisen B, van der Schoot CE, de Haas M. Blood group genotyping: from patient to high-throughput donor screening. *Vox Sang* 2009;97:198–206.
- Perreault J, Lavoie J, Painchaud P, *et al.* Set-up and routine use of a database of 10555 genotyped blood donors to facilitate the screening of compatible blood components for alloimmunized patients. *Vox Sang* 2009;87:61–68.
- Jungbauer C, Hobel CM, Schwartz DWM, Mayr WR. High-throughput multiplex PCR genotyping for 35 red blood cell antigens in blood donors. *Vox Sang* 2011;102: 234–242.
- Bombard AT, Akolekar R, Farkas DH, *et al.* Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitised RhD negative women. *Prenat Diagn* 2011;31:802–808.
- Monteiro F, Tavares G, Ferreira M, *et al.* Technologies involved in molecular blood group genotyping. *ISBT Sci Ser* 2011;6:1–6.
- ten Bosch JR, Grody WW. Keeping up with the next generation. Massively parallel sequencing in clinical diagnosis. *J Molec Diagn* 2008;10:484–492.